@misc{10481/90659,
year = {2009},
month = {7},
url = {https://hdl.handle.net/10481/90659},
abstract = {Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.},
publisher = {Bentham Science Publishers},
keywords = {Faropenem},
keywords = {Dalbavancin},
keywords = {Telavancin},
keywords = {Oritavancin},
keywords = {Ceftobiprole},
keywords = {Iclaprim},
title = {Antimicrobial development in the era of emerging resistance},
doi = {10.2174/138955709788681564},
author = {Sorlozano Puerto, Antonio and Carrasco, Cristina and Cabeza, José and Villegas Martínez, Enrique and Gutiérrez Fernández, José},
}